- Home
- YI vs INMB Comparison
YI vs INMB Comparison
Compare YI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YI | INMB |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 39.6M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | YI | INMB |
|---|---|---|
| Price | $4.13 | $1.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 34.6K | ★ 724.8K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $2.48 | $1.09 |
| 52 Week High | $11.17 | $3.24 |
Technical Indicators
Market Signals| Indicator | YI | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 66.12 |
| Support Level | $3.39 | $1.37 |
| Resistance Level | $4.88 | $1.76 |
| Average True Range (ATR) | 0.47 | 0.14 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 37.50 | 86.98 |
Price Performance
Historical ComparisonAbout YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.